MSD, Moderna Start Phase III Adjuvant Lung Cancer Trial

MSD and Moderna have kicked off another Phase III trial of their personalised cancer vaccine V940 used alongside MSD’s PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage NSCLC.